The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary artery bypass graft surgery.
Angiotensin-converting enzyme inhibitors have been shown to prolong survival, decrease infarct size, and improve ventricular function in patients who have congestive heart failure, and in those who have sustained a myocardial infarction. This review will summarize the evidence to show that angiotensin-converting enzyme inhibitors can also benefit patients undergoing coronary artery bypass graft surgery by minimizing perioperative ischemia, and reducing long-term cardiovascular events.
Lazar
Harold L
HL
Department of Cardiothoracic Surgery, Boston University School of Medicine and Boston Medical Center, 88 East Newton Street, B402, Boston, MA 02118, USA. harold.lazar@bmc.org
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000379:methods; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans
D000806:Angiotensin-Converting Enzyme Inhibitors